Thoracic Oncology Highlights 2015


The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did this E-Learning provide a general update on novelties in the treatment of patients with local/locally advanced and recurrent/metastatic non-small cell lung cancer (NSCLC), as well as for patients with malignant pleural mesothelioma? (1-no, not at all; 5-yes absolutely)

2. Did this E-Learning provide an update on the latest clinical research findings in a type of resection in early NSCLC, adjuvant therapy in resected NSCLC; immunotherapy in second-line NSCLC treatment; role of anti-EGFR tyrosine kinase inhibitors in unselected squamous NSCLC; treatment advances in NSCLC tumours with targetable oncogenic driver alterations, and first-line treatment for malignant pleural mesothelioma? (1-no, not at all; 5-yes absolutely)

3. Did this E-Learning put clinically meaningful findings into treatment perspective? (1-no, not at all; 5-yes absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: